within Pharmacolibrary.Drugs.ATC.V;

model V03AF12
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 8.483333333333333e-05,
    adminDuration  = 600,
    adminMass      = 240 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0241,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0134,
    k12             = 13.6,
    k21             = 13.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AF12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Trilaciclib is an intravenously administered, selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used to reduce the frequency and severity of chemotherapy-induced myelosuppression in adults receiving certain chemotherapeutic regimens for extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib is FDA-approved for this indication. It is not used as an anticancer agent directly, but as a myeloprotective agent to help patients tolerate myelosuppressive chemotherapy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model for adult cancer patients (predominantly ES-SCLC) receiving intravenous trilaciclib; parameters from first-in-human, phase 2, and phase 3 studies.</p><h4>References</h4><ol><li><p>Cheng, Y, et al., &amp; Zhou, L (2024). Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES). <i>Lung cancer (Amsterdam, Netherlands)</i> 188 107455–None. DOI:<a href=&quot;https://doi.org/10.1016/j.lungcan.2023.107455&quot;>10.1016/j.lungcan.2023.107455</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38224653/&quot;>https://pubmed.ncbi.nlm.nih.gov/38224653</a></p></li><li><p>Weiss, JM, et al., &amp; Dragnev, KH (2019). Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 30(10) 1613–1621. DOI:<a href=&quot;https://doi.org/10.1093/annonc/mdz278&quot;>10.1093/annonc/mdz278</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31504118/&quot;>https://pubmed.ncbi.nlm.nih.gov/31504118</a></p></li><li><p>Li, C, et al., &amp; Beelen, A (2023). Population pharmacokinetics and exposure-response of trilaciclib in extensive-stage small cell lung cancer and triple-negative breast cancer. <i>British journal of clinical pharmacology</i> 89(3) 1067–1079. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15549&quot;>10.1111/bcp.15549</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36180417/&quot;>https://pubmed.ncbi.nlm.nih.gov/36180417</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AF12;
